Search Results - "Stentoft, Jesper"

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial by Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, Saglio, Giuseppe

“…The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following…”
Get full text

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML by Warfvinge, Rebecca, Geironson, Linda, Sommarin, Mikael N.E., Lang, Stefan, Karlsson, Christine, Roschupkina, Teona, Stenke, Leif, Stentoft, Jesper, Olsson-Strömberg, Ulla, Hjorth-Hansen, Henrik, Mustjoki, Satu, Soneji, Shamit, Richter, Johan, Karlsson, Göran

“…Understanding leukemia heterogeneity is critical for the development of curative treatments as the failure to eliminate therapy-persistent leukemic stem cells…”
Get full text

Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma by Holst, Johanne M, Pedersen, Martin B, Enemark, Marie B, Hansen, Marcus C, Noerhave, Patrick R, Plesner, Trine L, Frederiksen, Henrik, Moeller, Michael B, Hamilton-Dutoit, Stephen J, Noergaard, Peter, Mortensen, Bo K, Ommen, Hans B, Stentoft, Jesper, Tam, Wayne, Ludvigsen, Maja, Chan, Wing C, Birkbak, Nicolai J, Inghirami, Giorgio, D'Amore, Francesco

“…Not available.Not available…”
Get full text

Evaluation of platelet function in thrombocytopenia by Skipper, Mette Tiedemann, Rubak, Peter, Stentoft, Jesper, Hvas, Anne-Mette, Larsen, Ole Halfdan

“…Whole blood aggregometry is a functional assay for determination of platelet function. Until now, whole blood aggregometry has not been considered feasible at…”
Get full text

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort by Holst, Johanne M, Plesner, Trine L, Pedersen, Martin B, Frederiksen, Henrik, Møller, Michael B, Clausen, Michael R, Hansen, Marcus C, Hamilton-Dutoit, Stephen Jacques, Nørgaard, Peter, Johansen, Preben, Ramm Eberlein, Tobias, Mortensen, Bo K, Mathiasen, Gustav, Øvlisen, Andreas, Wang, Rui, Wang, Chao, Zhang, Weiwei, Beier Ommen, Hans, Stentoft, Jesper, Ludvigsen, Maja, Tam, Wayne, Chan, Wing C, Inghirami, Giorgio, d'Amore, Francesco

“…Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative…”
Get full text

The Mozart effect in chronic myeloid leukaemia by Stentoft, Jesper

“…Clinical research has not been able to establish whether the differences between first‐ and second‐generation BCR‐ABL 1 kinase inhibitors are clinically…”
Get full text

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line by Kreutzman, Anna, Yadav, Bhagwan, Brummendorf, Tim H., Gjertsen, Bjorn Tore, Hee Lee, Moon, Janssen, Jeroen, Kasanen, Tiina, Koskenvesa, Perttu, Lotfi, Kourosh, Markevärn, Berit, Olsson-Strömberg, Ulla, Stentoft, Jesper, Stenke, Leif, Söderlund, Stina, Udby, Lene, Richter, Johan, Hjorth-Hansen, Henrik, Mustjoki, Satu

“…Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid…”
Get full text

P1610: VALIDATION AND CLINICAL CHARACTERISTICS OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND EVANS SYNDROME DIAGNOSES IN NATIONWIDE DANISH HEALTH REGISTERS by Lawrie, Dana, Hansen, Dennis Lund, Leineweber, Thomas Daell, Carlsen, Sarah Birgitte Ingemod Sand, Hannig, Louise Hur, Pedersen, Per Trøllund, Kristensen, Helene Bjørg, Lorenzen, Mads Okkels Birk, Stentoft, Jesper, Niekerk, Peter Buur Van Kooten, Jørgensen, Maren, Severinsen, Marianne, Dorff, Mikkel, Pedersen, Robert Schou, Glenthøj, Andreas, Frederiksen, Henrik

Get full text

Leukaemia Diagnosis, fifth edition. Barbara J.Bain, Wiley Blackwell,2017. ISBN 9781119210542 (cloth, 559 pages). Also available as e‐book by Stentoft, Jesper

Get full text

Validity assumptions for a multiple-choice test of medical knowledge with open-books and web access. A known groups comparison study by O'Neill, Lotte Dyhrberg, Simonsen, Eivind Ortind, Knudsen, Ulla Breth, Stentoft, Jesper, Jensen, Anders Bonde, Carlsen, Charlotte Green, Mørcke, Anne Mette

“…Relatively little evidence about the validity threats in open-book multiple-choice tests exist. The aim of this study was to examine validity aspects relating…”
Get full text

Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study by Frederiksen, Henrik, Dr, Farkas, Dóra Körmendiné, MSc, Christiansen, Christian Fynbo, PhD, Larsen, Thomas Stauffer, PhD, Hasselbalch, Hans Carl, DrMedSci, Stentoft, Jesper, PhD, Sørensen, Henrik Toft, DMedSci

“…Summary Background Patients with chronic myeloproliferative neoplasms are at increased risk of new solid or haematological cancers, but how prognosis is…”
Get full text

ITP: from idiopathic purpura to immune thrombocytopenia and back by Stentoft, Jesper

Get full text

Minimal residual core binding factor AMLs by real time quantitative PCR—Initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse by Stentoft, Jesper, Hokland, Peter, Østergaard, Mette, Hasle, Henrik, Nyvold, Charlotte Guldborg

“…Minimal residual disease (MRD) was measured by RQ-PCR in 11 AML1/ ETO and 13 CBFβ/ MYH11 patients at diagnosis, after induction chemotherapy, and at all…”
Get full text

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study by Ross, David M., Masszi, Tamas, Gómez Casares, María Teresa, Hellmann, Andrzej, Stentoft, Jesper, Conneally, Eibhlin, Garcia-Gutierrez, Valentin, Gattermann, Norbert, le Coutre, Philipp D., Martino, Bruno, Saussele, Susanne, Giles, Francis J., Radich, Jerald P., Saglio, Giuseppe, Deng, Weiping, Krunic, Nancy, Bédoucha, Véronique, Gopalakrishna, Prashanth, Hochhaus, Andreas

“…Purpose ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic…”
Get full text

How I treat immune thrombocytopenia – a global view by Cooper, Nichola, Bird, Robert, Chinthammitr, Yingyong, George, Biju, Stentoft, Jesper, Tomiyama, Yoshiaki, Zaja, Francesco, Hokland, Peter

Get full text

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts by Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O’Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., de Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Maria Bengio, Raquel, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, DeSouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori

“…As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the…”
Get full text

Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon by Hjorth-Hansen, Henrik, Mustjoki, Satu, Olsson-Strömberg, Ulla, Stentoft, Jesper, Efficace, Fabio, Johansson, Hemming, Brandberg, Yvonne

“…Background: Tyrosine kinase inhibitors (TKI) have revolutionized CML treatment but only a minority of patients are candidates to discontinue their TKI…”
Get full text

Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study by Christensen, Sarah Friis, Svingel, Lise Skovgaard, Kjærsgaard, Anders, Stenling, Anna, Paulsson, Björn, Andersen, Christen Lykkegaard, Christiansen, Christian Fynbo, Stentoft, Jesper, Starklint, Jørn, Severinsen, Marianne Tang, Clausen, Mette Borg, Hilsøe, Morten Hagemann, Frederiksen, Henrik, Hasselbalch, Hans C., Bak, Marie, Mikkelsen, Ellen Margrethe

“…▪ BACKGROUND Myeloproliferative neoplasms (MPNs) are characterized by a substantial symptom burden, risk of debilitating complications (e.g., thrombosis), and…”
Get full text

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia by Simonsson, Bengt, Gedde-Dahl, Tobias, Markevärn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Björeman, Mats, Flogegård, Max, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Ohm, Lotta, Räsänen, Anu, Sinisalo, Marjatta, Själander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin, Sandin, Fredrik, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, Porkka, Kimmo

“…Biologic and clinical observations suggest that combining imatinib with IFN-α may improve treatment outcome in chronic myeloid leukemia (CML). We randomized…”
Get full text

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN by Knudsen, Trine Alma, Hansen, Dennis Lund, Ocias, Lukas Frans, Bjerrum, Ole, Brabrand, Mette, Christensen, Sarah Friis, Eickhardt-Dalbøge, Christina Schjellerup, Ellervik, Christina, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Larsen, Morten Kranker, Mourits-Andersen, Torben, Möller, Sören, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Sørensen, Anders Lindholm, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas S., Hasselbalch, Hans C.

“…Background: Hydroxyurea (HU) is the most commonly used first-line cytoreductive treatment option for patients with myeloproliferative neoplasms (MPN)…”
Get full text